Following FDA Review, Pharmaxis to Accelerate Plans for PXS-5505 Combination Study with JAK Inhibitor in Myelofibrosis Patients
12th
Apr 23
Release Date: 12/04/2023 9:10am
- FDA Provides Feedback after Review of Interim Safety and Efficacy Data from Ongoing Monotherapy Trial MF-101
- Pharmaxis Plans to Commence Trial of Combination Therapy with Myelofibrosis Standard of Care Treatment in CY 2023
Categories: News and Media